Navigation Links
VentriPoint, University of Washington Sign Research and Technology Development Agreement

Projects Focus on Completion of the Congenital Heart Disease Database and the Further Transition of Knowledge and Processes to VentriPoint for the

Development of the VentriPoint Diagnostic System

SEATTLE, April 25 /PRNewswire-FirstCall/ -- VentriPoint(TM) Diagnostics Ltd. (TSX: VPT) today announced that it has finalized a research and technology development agreement with the University of Washington to collaborate on projects that will enhance and broaden the VentriPoint Diagnostic System (VDS) commercial offering.

Under the terms of the agreement, the University of Washington will expand its recruitment of leading institutions world-wide to participate in building comprehensive databases of right and left ventricle reconstructions representing specific heart diseases, such as congenital heart disease (CHD). These databases will be referenced by the VDS as it delivers three-dimensional models and analysis of patients' hearts based on anatomical points identified by doctors on two-dimensional scans.

"Our core technology was first developed at the University of Washington, so it makes sense to collaborate with their subject matter experts," said Joseph Ashley, CEO of VentriPoint Diagnostics. "The results of these projects will enhance and speed the commercial development of the VentriPoint Diagnostic System, which uses existing medical imaging systems to generate critical heart measurements in a rapid and inexpensive manner not currently available."

Under the agreement, the University of Washington will collaborate with VentriPoint to increase the size of the database used by the VDS by up to 160 additional CHD heart reconstructions of different conditions. The University of Washington will also continue its transition of knowledge and processes to VentriPoint, in support of the technology license. It will also commence recruitment of patients with pulmonary hypertension to begin development of a subsequent VDS application. Financial terms of the agreement were not disclosed.

About VentriPoint Diagnostics

VentriPoint creates diagnostic tools to monitor patients with heart disease -- the number one cause of death in developed countries. By using existing medical imaging systems, the VentriPoint Diagnostic System generates critical heart measurements in a rapid and inexpensive manner not currently available. This breakthrough diagnostic tool is based upon VentriPoint's technology license with the University of Washington. The VentriPoint Diagnostic System, together with its associated online service, is being developed for a variety of heart related disease states, including congenital heart disease.

For further information, please contact:

Edward Garth, Chief Financial Officer

VentriPoint Diagnostics Ltd.

Telephone: (206) 283-0221, ext. 402

Facsimile: (206) 283-2309

VentriPoint Media Contacts:

Russo Partners LLC

Ian Stone

(619) 814-3510

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

SOURCE VentriPoint Diagnostics Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sloning and the Kornberg group at Stanford University starting evaluation project regarding the synthesis of a Statistically Randomized Gene Library
2. Loma Linda University Partners With Larta Institute for Technology Marketing Program
3. Leading Geneticist Francis Collins Named First Recipient of the Inamori Ethics Prize at Case Western Reserve University
4. Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School
5. Open Biosystems Open Access RNAi Program Adopted by University of Copenhagen and University of Queensland
6. Lentigen Licenses Fundamental Lentiviral Vector Technology Patent From the University of Cambridge
7. Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer
8. Three CEOs and University President Named Winners of Greater Baltimore Committees 2008 Baltimore Region Bioscience Awards
9. Open Biosystems Open Access RNAi Program Adopted by Harvard Medical School and University of North Carolina
10. NeoStems Denis Rodgerson, Ph.D. to Lecture on Stem Cells and Regenerative Medicine at University of Nevada Las Vegas Campus
11. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
Post Your Comments:
(Date:10/9/2017)... 2017  BioTech Holdings announced today identification and ... ProCell stem cell therapy prevents limb loss in ... demonstrated that treatment with ProCell resulted in more ... compared to standard bone marrow stem cell administration.  ... reduction of therapeutic effect.  ...
(Date:10/9/2017)... , ... October 09, 2017 , ... ... four-tiered line of medical marijuana products targeting the needs of consumers who are ... of Kindred takes place in Phoenix, Arizona. , As operators of two successful ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially available ... bioinformatics software to perform Hi-C metagenome deconvolution using their own facilities, supplementing ...
(Date:10/6/2017)... ... October 06, 2017 , ... On Tuesday, October 24th, ABC² ... the first-ever adaptive clinical trial for glioblastoma (GBM). The featured speaker will be ... and open to the public, but registration is required. , WHAT: ABC² ...
Breaking Biology Technology:
(Date:8/15/2017)... 2017   ivWatch LLC , a medical device company focused ... announced receipt of its ISO 13485 Certification, the global standard for ... for Standardization (ISO®). ... 400 Continuous Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, ...
(Date:6/30/2017)... , June 30, 2017 Today, American ... and supplier of face and eye tracking software, ... Product provider program. "Artificial intelligence ... way to monitor a driver,s attentiveness levels while ... being able to detect fatigue and prevent potential ...
(Date:6/14/2017)... PARIS , June 15, 2017  IBM (NYSE: IBM ... the international tech event dedicated to developing collaboration between startups ... on June 15-17. During the event, nine startups will ... deliver value in various industries. ... in the international market, with a 30 percent increase in ...
Breaking Biology News(10 mins):